Literature DB >> 34413240

Huntington's disease: diagnosis and management.

Thomas B Stoker1, Sarah L Mason2, Julia C Greenland2, Simon T Holden3, Helen Santini4, Roger A Barker2,5.   

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disease characterised by neuropsychiatric symptoms, a movement disorder (most commonly choreiform) and progressive cognitive impairment. The diagnosis is usually confirmed through identification of an increased CAG repeat length in the huntingtin gene in a patient with clinical features of the condition. Though diagnosis is usually straightforward, unusual presentations can occur, and it can be difficult to know when someone has transitioned from being an asymptomatic carrier into the disease state. This has become increasingly important recently, with several putative disease-modifying therapies entering trials. A growing number of conditions can mimic HD, including rare genetic causes, which must be considered in the event of a negative HD genetic test. Patients are best managed in specialist multidisciplinary clinics, including when considering genetic testing. Current treatments are symptomatic, and largely directed at the chorea and neurobehavioural problems, although supporting trial evidence for these is often limited. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  genetics; huntington-s; movement disorders

Mesh:

Year:  2021        PMID: 34413240     DOI: 10.1136/practneurol-2021-003074

Source DB:  PubMed          Journal:  Pract Neurol        ISSN: 1474-7758


  5 in total

1.  Canadian healthcare capacity gaps for disease-modifying treatment in Huntington's disease: a survey of current practice and modelling of future needs.

Authors:  Angèle Bénard; Sylvain Chouinard; Blair R Leavitt; Nathalie Budd; Jennifer W Wu; Kerrie Schoffer
Journal:  BMJ Open       Date:  2022-06-01       Impact factor: 3.006

Review 2.  Effects of Exercise on Skeletal Muscle Pathophysiology in Huntington's Disease.

Authors:  Bruno Trovato; Benedetta Magrì; Alessandro Castorina; Grazia Maugeri; Velia D'Agata; Giuseppe Musumeci
Journal:  J Funct Morphol Kinesiol       Date:  2022-05-11

Review 3.  NAD+ Metabolism and Diseases with Motor Dysfunction.

Authors:  Samuel Lundt; Shinghua Ding
Journal:  Genes (Basel)       Date:  2021-11-09       Impact factor: 4.096

4.  Anti-Huntington's Effect of Rosiridin via Oxidative Stress/AchE Inhibition and Modulation of Succinate Dehydrogenase, Nitrite, and BDNF Levels against 3-Nitropropionic Acid in Rodents.

Authors:  Muhammad Afzal; Nadeem Sayyed; Khalid Saad Alharbi; Sami I Alzarea; Mohammed Salem Alshammari; Fadhel A Alomar; Sattam Khulaif Alenezi; Anwarulabedin Mohsin Quazi; Abdulaziz I Alzarea; Imran Kazmi
Journal:  Biomolecules       Date:  2022-07-23

Review 5.  Pathophysiology of Lipid Droplets in Neuroglia.

Authors:  Tina Smolič; Robert Zorec; Nina Vardjan
Journal:  Antioxidants (Basel)       Date:  2021-12-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.